Filing Details

Accession Number:
0001551986-19-000082
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-07-01 17:00:03
Reporting Period:
2019-06-28
Accepted Time:
2019-07-01 17:00:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1551986 Innovate Biopharmaceuticals Inc. INNT Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1721664 Sandeep Laumas C/O Innovate Biopharmaceuticals, Inc.,
8480 Honeycutt Road, Suite 120
Raleigh NC 27615
Ceo, Executive Chairman Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-28 4,000 $1.15 18,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 758,373 Indirect By Bearing Circle Capital LLC
Footnotes
  1. The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.1477 to $1.1500, inclusive. The reporting person undertakes to provide to Innovate Biopharmaceuticals, Inc., any security holder of Innovate Biopharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
  2. These shares are held by Bearing Circle Capital LLC. Dr. Laumas is affiliated with Bearing Circle Capital LLC and has voting and investment power over the shares held by Bearing Circle Capital LLC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.